TUSK THERAPEUTICS
Tusk Therapeutics is a privately-held, immuno-oncology company, focused on discovering and developing unique therapeutic antibodies that harness the power of the immune system for the treatment of cancer. The Company has established a growing, diversified pipeline of antibodies against a selection of both novel and validated targets that play an important role in the immune response to cancer. The Company’s programmes target the tumour microenvironment and exert their action through modulatio... n, activation and/ or depletion of these immune cells. Tusk has a world-class leadership team as well as outstanding scientific advisors, including top immuno oncology researchers, and the team has extensive biotech and pharma experience in antibody discovery and drug development, with a track record of bringing drugs from early stage discovery through to approval. The Company is based at the Stevenage Bioscience Catalyst in Stevenage, UK.
TUSK THERAPEUTICS
Industry:
Health Care Therapeutics
Founded:
2014-01-01
Address:
Stevenage, Herefordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.tusktherapeutics.com
Total Employee:
11+
Status:
Closed
Total Funding:
2.5 M GBP
Technology used in webpage:
Safenames
Similar Organizations
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Jounce Therapeutics
Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.
STipe Therapeutics
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer.
Founder
Investors List
Innovate UK
Innovate UK investment in Grant - Tusk Therapeutics
Official Site Inspections
http://www.tusktherapeutics.com
- Host name: redirect.idp365.net
- IP address: 217.19.248.132
- Location: Milton Keynes United Kingdom
- Latitude: 52.0675
- Longitude: -0.7569
- Timezone: Europe/London
- Postal: MK14
More informations about "Tusk Therapeutics"
Tusk Therapeutics - Crunchbase Company Profile & Funding
Tusk Therapeutics is a privately-held, immuno-oncology company, focused on discovering and developing unique therapeutic antibodies that harness the power of the immune system for the …See details»
Tusk Therapeutics - VentureRadar
Tusk Therapeutics is a privately held immuno-oncology company focused on discovering and developing therapeutic antibodies that harness the power of the immune system to transform …See details»
Tusk Therapeutics 2025 Company Profile: Valuation, …
Tusk Therapeutics is headquartered in Stevenage, United Kingdom. What is the size of Tusk Therapeutics? Tusk Therapeutics has 7 total employees. What …See details»
Droia Ventures – Investing in Impact – Life Science
Oct 7, 2024 Our whole organization is geared towards doing what we do best: building great drug development companies. Portfolio. Accent Therapeutics (Lexington, Massachusetts) is …See details»
Press Release Distribution and Management - GlobeNewswire
Tusk Therapeutics presents data on to its anti-CD25 programme at AACR Annual Meeting 2018 ~ A first-in-class anti-CD25 Treg depleting antibody which enables Teff responses for optimal …See details»
Roche acquires Tusk Therapeutics in up to $759m deal
Roche has acquired UK-based immuno-oncology company Tusk Therapeutics in a deal valued at up to €655m ($759m). As per the terms of the agreement, Roche will make an upfront …See details»
Tusk Therapeutics to be acquired by Roche - stevenagecatalyst.com
Tusk Therapeutics Ltd. Luc Dochez, Chief Executive Officer [email protected]. About Tusk Therapeutics Ltd. Tusk Therapeutics is a privately held immuno-oncology company …See details»
Vico Therapeutics
Luc Dochez is the Chairman and co-founder of Vico Therapeutics. He has been a Managing Partner at Droia Ventures since December 2018. Previously, Luc was Chief Executive Officer …See details»
Tusk Therapeutics - Raised Funding from 1 investor - Tracxn
Feb 21, 2025 METYCLE - Cologne based, raised a funding of $14.7M in Series A round held on Feb 20, 2025.; RepScan - raised a funding of $3.13M in Series A round held on Feb 20, 2025.; …See details»
Tusk Therapeutics Ltd. - BioCentury Company Profiles - BCIQ
Tusk Therapeutics Ltd. - BioCentury Company Profiles for the biopharma industrySee details»
Tusk Therapeutics Ltd. - life-sciences-europe.com
Jan 1, 2014 Upcoming Events. BioChina 2025 Suzhou; BIO-Europe Spring 2025 Milano (Milan) AM Forum 2025 Berlin; Advanced Therapies 2025 London; VentureCon Bioeconomy 2025 …See details»
Roche pays €70M upfront for Tusk’s preclinical Treg depleter
Sep 28, 2018 Roche has paid €70 million ($81 million) upfront to buy Tusk Therapeutics. The takeover gives Roche control of an anti-CD25 antibody that depleted levels of regulatory T …See details»
Tusk Therapeutics - Tech Stack, Apps, Patents & Trademarks
Organization. Tusk Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Total Products Active 19. Active …See details»
Leadership Team & Board of Directors
Prior to that, he served as CMO of Tusk Therapeutics, an immuno-oncology company acquired by Roche, where he oversaw development of antibodies targeting CD25 and CD137, among …See details»
Kevin Moulder - StarBio International Ltd | LinkedIn
Joint UK/US citizen Drug Discovery: Proven successful development and… · StarBio International Ltd · Greater Cambridge Area · 500+ connections on LinkedIn. View Kevin Moulder’s profile …See details»
How UK researchers commercialised CD25 as an immunotherapy …
Tusk Therapeutics became excited by the CD25 data, and told Quezada if he could patent it, they would license it. An essential element of this deal was a provision allowing Quezada’s lab to …See details»
Breaking new ground to advance science with the potential to …
About Us The Beam Team. A team united by a passion to innovate. An organization revolutionizing gene-based editing, one letter at a time. About usSee details»
COMPOUNDS AND METHODS FOR TUMOUR-SPECIFIC CELL …
TUSK THERAPEUTICS LTD. (Welwyn Garden City, Hertfordshire, GB) CANCER RESEARCH TECHNOLOGY LIMITED (London, GB) International Classes: C07K16/28; A61P35/00. View …See details»
Vico Therapeutics Announces $60 million (€54 million) Series B ...
Luc Dochez is the Chairman and co-founder of Vico Therapeutics. He has been a Managing Partner at Droia Ventures since December 2018. Previously, Luc was Chief Executive Officer …See details»
Tusk Therapeutics Ltd._投融资最新情况_摩熵医药(原药融云)
Tusk Therapeutics是一家私营的免疫肿瘤学公司，专注于发现和开发利用免疫系统的力量治疗癌症的独特治疗性抗体。 该公司已经建立了一个不断增长的，多样化的抗体管道，针对选择的新 …See details»